Dakovir-C 60 mg (Tablet)
Unit Price: ৳ 400.00 (1 x 14: ৳ 5,600.00)
Strip Price: ৳ 5,600.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Daclatasvir |
| Company | Bristol myers squibb |
Indications
- Treatment of chronic hepatitis C virus (HCV) infection in adults
Pharmacology
- Direct acting antiviral agent against the Hepatitis C Virus (HCV)
- Inhibitor of NS5A protein, leading to inhibition of viral RNA replication and virion assembly
Dosage & Administration
- Recommended dose of 60 mg once daily
- To be taken orally with or without meals
- To be administered in combination with other medicinal products
- Data available for 12-week treatment duration for treatment-naïve patients with genotype 1 infection
Interaction
- Potential for other drugs to affect Dakovir-C
- Potential for Dakovir-C to affect other drugs
- Substrate of CYP3A
- Inhibitor of P-glycoprotein transporter, OATP 1B1 and 1B3, and BCRP
- Interaction with moderate or strong inducers/inhibitors of CYP3A and other drugs
Contraindications
- Contraindicated in combination with drugs that strongly induce CYP3A, such as Anticonvulsants, Antimycobacterial agents, and Herbal Products st.John's wort
Side Effects
- Serious symptomatic bradycardia when coadministered with Sofosbuvir and Amiodarone
- Possible symptoms include fainting, dizziness, weakness, shortness of breath, chest pain, confusion
Pregnancy & Lactation
- No data available for pregnant women
- No information regarding presence in human milk or effects on the breastfed infant
Precautions & Warnings
- Risk of adverse reactions or loss of virologic response due to drug interactions
- Possible drug interactions leading to loss of therapeutic effect, dosage adjustments, or adverse reactions
- Serious symptomatic bradycardia when coadministered with Sofosbuvir and Amiodarone
- Patient counseling and cardiac monitoring for those starting Amiodarone therapy
Use in Special Populations
- No dose adjustment required for elderly patients
- No dose adjustment required for patients with renal impairment
- No dose adjustment required for patients with mild, moderate, or severe hepatic impairment
- Safety and efficacy in children and adolescents not established
Overdose Effects
- No known antidote for overdose
- Supportive measures and monitoring of vital signs recommended
- Dialysis unlikely to significantly reduce plasma concentrations
Therapeutic Class
- Hepatic viral infections (Hepatitis C)
Storage Conditions
- Store at room temperature below 30°C
- Protect from light
- Keep out of the reach of children